Sugi Predict

Sugi Predict / Compounds / SCHEMBL1106491

SCHEMBL1106491

SCHEMBL1106491

Cc1ccc(=O)n(C(C)C)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ BLM P54132 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ POLB P06746 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ ADORA2A P29274 1/20 0.39
▸ ADORA1 P30542 1/20 0.39
▸ BMPR1A P36894 11/20 0.38
▸ ACVRL1 P37023 11/20 0.38
▸ ACVR1 Q04771 11/20 0.38
▸ BMPR1B O00238 10/20 0.38
▸ TGFBR1 P36897 9/20 0.38
▸ PTGDR2 Q9Y5Y4 3/20 0.38
▸ PTGS2 P35354 1/20 0.37
▸ PDE10A Q9Y233 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15046628 0.80 PTGS2 (0.51) KDM4EALDH1A1CYP1A2HPGDBLM
SCHEMBL19677340 0.79 ALDH1A1 (0.41) KDM4EALDH1A1CYP1A2HPGDBLM
SCHEMBL14757564 0.76 ADORA2A (0.38) ADORA2AADORA1BMPR1AACVRL1ACVR1
SCHEMBL20048155 0.76 ADORA2A (0.44) ADORA2AADORA1BMPR1AACVRL1ACVR1
SCHEMBL27446368 0.76 PTGS2 (0.40) KDM4EALDH1A1MAPTADORA2AADORA1
SCHEMBL10119732 0.76 PTGS2 (0.47) KDM4EALDH1A1ADORA2AADORA1BMPR1A
SCHEMBL506044 0.76 ADORA2A (0.38) ALDH1A1ADORA2AADORA1BMPR1AACVRL1
SCHEMBL1106469 0.76 PTGDR2 (0.42) KDM4EALDH1A1MAPTADORA2AADORA1
SCHEMBL1106476 0.76 ADORA2A (0.51) ADORA2AADORA1BMPR1AACVRL1ACVR1
SCHEMBL628269 0.76 ADORA2A (0.38) ADORA2AADORA1BMPR1AACVRL1ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 — — WO disclosed
US-20240228469-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-07-11 — — US disclosed
US-20240217951-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-07-04 — — US disclosed
WO-2024126773-A1 IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-06-20 — — WO disclosed
WO-2024062090-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-03-28 — — WO disclosed
WO-2024062089-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-03-28 — — WO disclosed
US-11787780-B2 Quaternary indazole glucocorticoid receptor antagonists CORCEPT THERAPEUTICS INCORPORATED (US) 2023-10-17 — — US disclosed
US-11771738-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2023-10-03 — — US disclosed
US-11771738-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2023-10-03 — — US disclosed
WO-2023154282-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2023-08-17 — — WO disclosed
EP-2090570-B1 IMIDAZOLE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2011-11-09 — — EP disclosed
US-20100210641-A1 Organic Compounds NOVARTIS AG (CH) 2010-08-19 — — US disclosed
US-20100210641-A1 Organic Compounds NOVARTIS AG (CH) 2010-08-19 — — US disclosed
US-20100152178-A1 IMIDAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-17 — — US disclosed
US-20100152178-A1 IMIDAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-17 — — US disclosed
US-20090298806-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2009-12-03 — — US disclosed
US-20090298806-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2009-12-03 — — US disclosed
EP-2090570-A1 IMIDAZOLE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2009-08-19 — — EP disclosed
WO-2009050183-A2 IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS NOVARTIS AG (CH) 2009-04-23 — — WO disclosed
US-7521470-B2 Factor Xa inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787780-B2 Quaternary indazole glucocorticoid receptor antagonists NR3C1, NR3C2, MC2R KDM4E 3007/4885ALDH1A1 2702/4885CYP1A2 203/4885
US-20100210641-A1 Organic Compounds ALK, ACVR1, ACVRL1 KDM4E 448/4885ALDH1A1 1069/4885CYP1A2 1051/4885
US-20090298806-A1 FACTOR XA INHIBITORS TFPI, F12, F11 KDM4E 2875/4885ALDH1A1 974/4885CYP1A2 117/4885
US-20240228469-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF PCSK9, PCSK7, PCSK6 KDM4E 3520/4885ALDH1A1 3112/4885CYP1A2 1091/4885
US-20240217951-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF PCSK9, PCSK7, PCSK6 KDM4E 3138/4885ALDH1A1 1920/4885CYP1A2 876/4885
US-11771738-B2 Endoparasitic depsipeptides VIP, PREP, VIPR1 KDM4E 4092/4885ALDH1A1 2109/4885CYP1A2 1888/4885
US-20100152178-A1 IMIDAZOLE DERIVATIVES CNR1, CNR2, ARRB1 KDM4E 2340/4885ALDH1A1 2997/4885CYP1A2 590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.